Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Univariate and multivariate analysis of clinicopathological factors with serum osteopontin level (A), serum thrombospondin-1 level (B), serum OPN/TSP-1 ratio (C) for overall survival

From: Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer

   Univariate analysis Multivariate analysis
   HR 95 % CI p value HR 95 % CI p value
A. Factors associated with serum osteopontin level for overall survival
Osteopontin Serum levela 1.95 1.15–3.32 0.01 1.71 1.04–2.82 0.04
Stage I to IIIA vs IIIB 0.26 0.11–0.61 0.002 0.29 1.04–0.68 0.01
Pleural involvement Positive vs Negative 1.94 0.93–4.04 0.08 1.11 0.66–1.57 0.73
Lympho-vascular invasion Positive vs Negative 2.47 1.21–5.03 0.01 1.27 0.56–2.85 0.57
Adjuvant treatment No vs Yes 1.32 0.63–2.73 0.51
Age ≥65 vs <65 1.61 0.75–3.46 0.24
Gender Male vs female 1.14 0.56–2.34 0.73
Smoking history Smoker vs non-smoker 1.14 0.44–2.96 0.80
B. Factors associated with serum thrombospondin-1 level for overall survival
Thrombospondin-1 Serum levelb 0.15 0.03–0.89 0.04 0.18 0.04–0.87 0.03
Stage I to IIIA vs IIIB 0.26 0.11–0.61 0.002 0.26 0.11–0.61 0.002
Pleural involvement Positive vs Negative 1.94 0.93–4.04 0.08 1.13 0.36–1.37 0.69
Lympho-vascular invasion Positive vs Negative 2.47 1.21–5.03 0.01 1.28 0.58–2.84 0.54
Adjuvant treatment No vs Yes 1.32 0.63–2.73 0.51
Age ≥65 vs <65 1.61 0.75–3.46 0.24
Gender Male vs female 1.14 0.56–2.34 0.73
Smoking history Smoker vs non-smoker 1.14 0.44–2.96 0.80
C. Factors associated with serum osteopontin/thrombospondin-1 ratio for overall survival
OPN/TSP1 Ratioc 1.40 1.08–1.81 0.01 1.31 1.03–1.67 0.03
Stage I to IIIA vs IIIB 0.26 0.11–0.61 0.002 0.29 0.12–0.68 0.01
Pleural involvement Positive vs Negative 1.94 0.93–4.04 0.08 0.75 0.24–0.97 0.38
Lympho-vascular invasion Positive vs Negative 2.47 1.21–5.03 0.01 0.62 0.23–0.89 0.27
Adjuvant treatment No vs Yes 1.32 0.63–2.73 0.51
Age ≥65 vs <65 1.61 0.75–3.46 0.24
Gender Male vs female 1.14 0.56–2.34 0.73
Smoking history Smoker vs non-smoker 1.14 0.44–2.96 0.80
  1. HR Hazard Ratio, 95 % CI 95 % Confidence interval
  2. afor an increment in OPN of 50 ng/mL
  3. bfor an increment in TSP-1 of 10 ng/mL in log10 scale
  4. cfor an increment of 6 ng/mL in the ratio OPN/log10 (TSP1)